Articles related to Cardiology, Interventional

The oral suspension formulation was developed for patients who have difficulty swallowing the tablet form of the PDE5 inhibitor.

In this commentary, the editor-in-chief of CCJM considers what is known, and what is still mystery about how the heart and kidneys are modified during chronic heart failure, and discusses how much of our therapy remains empiric and experience-based.

Up to this point, individuals with non-alcoholic fatty liver disease (NAFLD) and a normal BMI have often been overlooked. It was assumed their normal BMI equated to a lower risk of more serious conditions than those who are overweight or obese. These findings indicate that lean patients with NAFLD are 50% more likely to have a CVA compared with overweight patients, and 10 to 30% more likely to experience CVD.

Seven-hundred patients with left ventricular ejection fraction (LVEF) of 35% or less, extensive coronary artery disease amenable to PCI, and demonstrable myocardial viability were randomly assigned to PCI plus optimal medical therapy vs. optimal medical therapy alone. At 6 months, the LVEF was similar between the two groups.

The IV-equivalent formulation is indicated for the treatment of congestion due to fluid overload in people with NYHA class II/III chronic heart failure and may offer a substantial change in the management of the condition.

When compared with rivaroxaban in a propensity score–matched cohort of 19,894 patients, apixaban was associated with an approximately 50% lower rate of ischemic stroke or systemic embolism and bleeding compared to rivaroxaban.